Iscalimab (CFZ533) in Patients with Sjogren's Disease: Week 24 Efficacy and Safety Results of a Randomized, Placebo-controlled, Phase 2b Dose-ranging Study

被引：0

作者：

Fisher, Benjamin A. ^{[1
]}

Mariette, Xavier ^{[2
]}

Papas, Athena S. ^{[3
]}

Grader-Beck, Thomas ^{[4
]}

Bootsma, Hendrika ^{[5
]}

Ng, Wan-Fai ^{[6
]}

Van Daele, Paul ^{[7
]}

Finzel, Stephanie ^{[8
]}

Elgueta, Sergio ^{[9
]}

Hermann, Josef ^{[10
]}

McCoy, Sara ^{[11
]}

Bookman, Arthur ^{[12
]}

Sopala, Monika ^{[13
]}

Luo, Wen-Lin ^{[14
]}

Scheurer, Cornelia ^{[13
]}

Hueber, Wolfgang ^{[13
]}

机构：

[1] Univ Birmingham, Birmingham, W Midlands, England

[2] Univ Paris Saclay, Le Kremlin Bicetre, France

[3] Tufts Sch Dent Med, Div Oral Med, Boston, MA USA

[4] Johns Hopkins Sch Med, Div Rheumatol, Baltimore, MD USA

[5] Univ Med Ctr Groningen, Dept Rheumatol, Groningen, Netherlands

[6] Newcastle Tyne Hosp NHS Fdn Trust, NIHR Newcastle Clin Res Facil, Newcastle Upon Tyne, Tyne & Wear, England

[7] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands

[8] Univ Freiburg, Univ Med Ctr Freiburg, Dept Rheumatol & Clin Immunol, Freiburg, Germany

[9] Clin Res Chile SpA, Biomed Res Ctr, Valdivia, Chile

[10] Med Univ Graz, Dept Internal Med, Div Rheumatol & Immunol, Graz, Austria

[11] Univ Wisconsin, Sch Med & Publ Hlth, Middleton, WI USA

[12] Toronto Western Hosp, Toronto, ON, Canada

[13] Novartis Pharma AG, Basel, Switzerland

[14] Novartis Pharmaceut, E Hanover, NJ USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1634

引用

下载

页码：3242 / 3244

页数：3

共 50 条

[41] Late Breaking Abstract - Efficacy and safety of eliapixant in refractory chronic cough: Results of the PAGANINI 12-week, randomized, placebo-controlled Phase 2b study
McGarvey, Lorcan
Morice, Alyn H.
Smith, Jaclyn
Sher, Mandel
Vaezi, Michael
Guilleminault, Laurent
Niimi, Akio
Roth, Katrin
Saarinen, Riitta
Pires, Philippe Vieira
Wosnitza, Melanie
Dicpinigaitis, Peter
EUROPEAN RESPIRATORY JOURNAL, 2021, 58
[42] A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis
Gupta, AK
Leonardi, C
Stoltz, RR
Pierce, PF
Conetta, B
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2005, 19 (04) : 437 - 443
[43] The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment - Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial
Emery, P
Fleischmann, R
Filipowicz-Sosnowska, A
Schechtman, J
Szczepanski, L
Kavanaugh, A
Racewicz, AJ
Van Vollenhoven, RF
Li, NF
Agarwal, S
Hessey, EW
Shaw, TM
ARTHRITIS AND RHEUMATISM, 2006, 54 (05): : 1390 - 1400
[44] A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause
Fraser, Graeme L.
Lederman, Samuel
Waldbaum, Arthur
Kroll, Robin
Santoro, Nanette
Lee, Misun
Skillern, Laurence
Ramael, Steven
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2020, 27 (04): : 382 - 392
[45] Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a 24-week randomized, placebo-controlled trial (ASSERT)
van der Heijde, D
Dijkmans, B
Geusens, P
Sieper, J
DeWoody, K
Williamson, R
Braun, J
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 403 - 403
[46] A 12-WEEK, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PHASE 2B STUDY OF SAFETY, TOLERABILITY AND EFFICACY OF AR882 IN GOUT PATIENTS
Wei, J. C. C.
Fleischmann, R. M.
Morris, S.
Polvent, E.
Shen, Z.
Roche, A. Clouser
Hingorani, V.
Yan, S.
Yeh, L. T.
Keenan, R.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 192 - 192
[47] Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study
Papp, K. A.
Langley, R. G.
Sigurgeirsson, B.
Abe, M.
Baker, D. R.
Konno, P.
Haemmerle, S.
Thurston, H. J.
Papavassilis, C.
Richards, H. B.
BRITISH JOURNAL OF DERMATOLOGY, 2013, 168 (02) : 412 - 421
[48] Efficacy, Safety, and Tolerability of Pridopidine in Huntington Disease (HD): Results from the Phase II, Double-blind, Placebo-controlled, Dose-Ranging Study, Pride-HD
Kieburtz, Karl
Landwehrmeyer, G. Bernhard
Reilmann, Ralf
Savola, Juha
Eyal, Eli
Grachev, Igor
Borowsky, Beth
McGarry, Andrew
Papapetropoulos, Spyros
Hayden, Michael
NEUROLOGY, 2017, 88
[49] Safety and efficacy of an oral insulin (Capsulin) in patients with early-stage type 2 diabetes: A dose-ranging phase 2b study
New, Roger R. C.
Sukumar, R.
Chaudhari, Varsha
Bogus, Michal
Travers, Glen N. N.
Namjoshi, Gajanan
DIABETES OBESITY & METABOLISM, 2023, 25 (04): : 953 - 960
[50] Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes
Rubin, Cindy J.
Viraswami-Appanna, Kalyanee
Fiedorek, Fred T.
DIABETES & VASCULAR DISEASE RESEARCH, 2009, 6 (03): : 205 - 215

← 1 2 3 4 5 →